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Abstract
Introduction: Breastfeeding has been inversely related to breast cancer risk in the general population. Clarifying
the role of breastfeeding among women with a BRCA1 or BRCA2 mutation may be helpful for risk assessment and
for recommendations regarding prevention. We present an updated analysis of breastfeeding and risk of breast
cancer using a large matched sample of BRCA mutation carriers.
Methods: We conducted a case-control study of 1,665 pairs of women with a deleterious mutation in either BRCA1
(n = 1,243 pairs) or BRCA2 (n = 422 pairs). Breast cancer cases and unaffected controls were matched on year of
birth, mutation status, country of residence and parity. Information about reproductive factors, including
breastfeeding for each live birth, was collected from a routinely administered questionnaire. Conditional logistic
regression was used to estimate the association between ever having breastfed, as well as total duration of
breastfeeding, and the risk of breast cancer.
Results: Among BRCA1 mutation carriers, breastfeeding for at least one year was associated with a 32% reduction in
risk (OR = 0.68; 95% CI 0.52 to 0.91; P = 0.008); breastfeeding for two or more years conferred a greater reduction in risk
(OR = 0.51; 95% CI 0.35 to 0.74). Among BRCA2 mutation carriers, there was no significant association between
breastfeeding for at least one year and breast cancer risk (OR = 0.83; 95% CI 0.53 to 1.31; P = 0.43).
Conclusions: These data extend our previous findings that breastfeeding protects against BRCA1-, but not BRCA2-
associated breast cancer. BRCA mutation carriers should be advised of the benefit of breastfeeding in terms of
reducing breast cancer risk.
Introduction
In the general population, reproductive factors, including
late age at menarche, parity and breastfeeding, have been
shown to protect against the development of breast can-
cer [1-3]. Various proposed mechanisms include redu-
cing lifetime exposure to ovarian hormones, reducing the
cumulative number of ovulatory cycles and differentia-
tion of the breast lobules [4,5]. We and others have eval-
uated the impact of reproductive factors in the etiology
of BRCA-associated breast cancer, although the results
are conflicting and vary by BRCA1 or BRCA2 mutation
[6-8]. With respect to breastfeeding and breast cancer
risk in BRCA1 mutation carriers, two previous studies
reported no relationship [9,10] and three studies reported
a protective effect [11,12]. One case-control study of
BRCA2 mutation carriers reported no association
between breastfeeding and breast cancer risk [8].
We have previously reported in a study of 965 matched
pairs that the total duration of breastfeeding was asso-
ciated with a significant reduction in breast cancer risk
among BRCA1, but not among BRCA2, mutation carriers
[11]. The association was particularly strong for breast-
feeding for more than one year (OR = 0.55; 95% CI 0.38
to 0.80). No association was seen for BRCA2 mutation
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carriers (OR = 0.95; 95% CI 0.59 to 1.59). Here we update
the analysis of total duration of breastfeeding and risk of
breast cancer using a larger sample of BRCA mutation
carriers with the addition of 700 matched pairs. Because
childbirth and breastfeeding are strongly correlated, we
restricted the present analysis to parous women and we
matched on parity to eliminate any potential confound-
ing effect of parity.
Methods
Study population
Eligible study subjects were identified at one of 62 parti-
cipating centers in seven countries. These women were
participants in ongoing research protocols at the host
institutions. These women sought testing for BRCA1
and BRCA2 mutations because of a personal and/or
family history of breast and/or ovarian cancer. All study
subjects, (with the exception of some participants from
the research study of SLN), received genetic counselling.
The institutional review boards of the host institutions
approved the study. All subjects provided written
informed consent. In most cases, testing was initially
offered to women who had been previously diagnosed
with breast or ovarian cancer. When a BRCA1 or
BRCA2 mutation was identified in a proband or her
relative, genetic testing was offered to other at-risk indi-
viduals in the family. Mutation detection was performed
using a range of techniques, but all nucleotide sequences
were confirmed by direct sequencing of DNA. A woman
was eligible for the current study when the molecular
analysis established that she was a carrier of a deleter-
ious mutation in the BRCA1 or BRCA2 gene.
Data collection
All study subjects completed a baseline questionnaire at
the individual center at the time of a clinic appointment
or at their home at a later date. The questionnaire
requested information on family and personal history of
cancer, reproductive and medical histories, including
preventive oophorectomy and mastectomy. Detailed
information regarding ages at menarche and menopause,
cause of menopause, pregnancy, breastfeeding history,
and hormone use was also queried. For each live birth,
women were asked to recall how long they breastfed
each child and to indicate the number of months of
breastfeeding. We estimated the total duration of breast-
feeding for each woman by summing the months of
breastfeeding for each live birth.
Case and control subjects
Information on cancer status was available for a total of
12,116 women who carried a BRCA1 or BRCA2 muta-
tion. Case subjects were women with a diagnosis of
invasive breast cancer. Control subjects were women
who never had breast cancer and who were also carriers
of a mutation in BRCA1 or BRCA2. Potential subjects
were excluded if they were nulliparous (n = 2,626) or if
information on parity (including year of last birth) was
missing (n = 320), if they had been diagnosed with ovar-
ian or other cancer (n = 2,325), if information on breast-
feeding was missing (n = 721), if BRCA mutation status
was missing (n = 191) or if other pertinent information
was missing (n = 54). After exclusions, there was a total
of 5,879 eligible women, including 2,784 women with
breast cancer (potential case subjects) and 3,095 women
without breast cancer (potential control subjects).
A single control subject was selected for each case sub-
ject, matched according to mutation in the same gene
(BRCA1 or BRCA2), year of birth (within one year), coun-
try of residence (Poland, USA, Canada, Israel, Austria,
Italy, United Kingdom), and parity (number of births). We
only included live births one or more years prior to the
breast cancer diagnosis of the case for both the cases and
controls. A control was eligible to be matched to a given
case if the date of interview or date of prophylactic mas-
tectomy in the matched control occurred at or after the
year of breast cancer diagnosis of the case and if the last
live birth of the control was at least one calendar year
prior to the year of breast cancer diagnosis of the case. In
total, 1,665 matched sets were identified. An appropriate
match could not be located for 1,119 of the eligible cases
because the date of birth of these cases (mean year of
birth 1947.99; range 1901 to 1981) was substantially earlier
compared to the pool of remaining controls (mean year of
birth 1966.57; range 1903 to 1989).
Statistical analysis
A matched case-control analysis was performed to evalu-
ate the association between breastfeeding and the risk of
breast cancer. We censored breastfeeding one year prior
to the diagnosis of the matched case. The distributions of
continuous and categorical variables between cases and
controls were compared using the Student’s t-test and
chi-square test, respectively. Conditional logistic regres-
sion was used to estimate the univariate odds ratios (OR)
and 95% confidence intervals (CI) for breast cancer asso-
ciated with breastfeeding (ever/never) and total duration
of breastfeeding (months). A multivariate analysis was
carried out to control for potential confounders. All ana-
lyses were performed using the SAS statistical package,
version 9.1.3 (SAS Institute, Cary, NC, USA). All P-values
were based on two-sided tests and were considered statis-
tically significant if P ≤ 0.05.
Results
Case and control subjects were similar with respect to
year of birth, oral contraceptive use, age at last birth,
smoking status and body mass index (BMI) at age 30
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(Table 1). Cases with a BRCA1 mutation had a signifi-
cantly earlier age at menarche than controls (13.09 years
vs. 13.27 years; P = 0.003) and were less likely to have
consumed alcohol (61% vs. 67%; P = 0.002). Although
not significant, age at first birth (24.8 vs. 25.1; P = 0.08)
and age at last birth (29.0 vs. 29.3; P = 0.06) were, on
average, earlier in BRCA1 mutation carriers compared
with controls. Hormone replacement therapy (HRT) use
was significantly lower in both BRCA1 and BRCA2 cases
versus controls (5% vs. 12%; P < 0.0001 and 10.7% vs.
16.5%; P = 0.02, respectively). Age at menarche, age at
first birth, age at last birth, mean duration of breastfeed-
ing and alcohol consumption did not differ between
cases and controls with a BRCA2 mutation.
The mean duration of breastfeeding was shorter among
the cases than the controls with a BRCA1 mutation (8.8
months vs. 10.4 months; P = 0.0009). There was a signifi-
cant reduction in breast cancer risk with breastfeeding
among women with a BRCA1 but not a BRCA2 mutation
(Table 2). On average, BRCA1 cases breastfed for 1.6
fewer months than controls (8.8 vs. 10.4 months P =
0.0009). There was only a 0.5-month difference between
cases and controls with a BRCA2 mutation (10.2 vs. 9.7
months P = 0.56). Among BRCA1 mutation carriers,
breastfeeding for at least one year was associated with a
32% reduction in risk (OR = 0.68; 95% CI 0.52 to 0.91; P
= 0.008); breastfeeding for two or more years conferred
an even stronger reduction in risk (OR = 0.51; 95% CI
0.35 to 0.74; P = 0.0003). Each year of breastfeeding con-
ferred a 19% reduction in risk. The effect of breastfeeding
was present for women diagnosed at all ages. The reduc-
tion in risk associated with breastfeeding for one or more
years compared with never breastfeeding was 44% for
women with an age at breast cancer diagnosis of ≤ 39
(OR = 0.56; 95% CI 0.33 to 0.96), 54% for those with an
age at diagnosis of 40 to 49 (OR = 0.46; 95% CI 0.26 to
.81) and 69% for those with an age at diagnosis of ≥ 50
(OR = 0.31; 95% CI 0.07 to 1.30).
Among BRCA2 mutation carriers, there was no signifi-
cant association between breastfeeding for at least one
year and breast cancer risk (OR = 0.83; 95% CI 0.53 to
1.31; P = 0.43). There was no relationship following
stratification by age at diagnosis. The risk estimates
associated with breastfeeding for one or more years
Table 1 Baseline characteristics of breast cancer cases and controls with BRCA1 and BRCA2 mutations.
Characteristic BRCA1 BRCA2
Controls
(n = 1,243)
Cases
(n = 1,243)
P Controls
(n = 422)
Cases
(n = 422)
P
Year of birth, mean (range) 1957.5 (1920-1980) 1957.3 (1920-1980) 0.71 1954.4 (1924-1978) 1955.3 (1924-1978) 0.82
Age at diagnosis, mean (range) n/a1 0.71 n/a1 n/a1 42.7 (24-67) n/a1
Country of residence, n (%)
Poland 601 (48%) matched 0 (0%) matched
USA 323 (26%) 187 (44%)
Canada 265 (21%) 218 (52%)
Israel 29 (2%) 13 (3%)
Austria 18 (1.5%) 3 (0.7%)
Italy 5 (0.4%) 0 (0%)
United Kingdom 2 (0.2%) 2 (0.5%)
Age at menarche, mean (range) 13.27(8-28) 13.09 (9-21) 0.003 12.64 (8-28) 12.15 (9-17) 0.88
Age at first birth, mean (range) 25.1 (15-44) 24.8 (15-42) 0.08 26.6 (17-44) 26.3 (16-42) 0.37
Age at last birth, mean (range) 29.3 (16-45) 29.0 (17-44) 0.06 30.5 (20-45) 30.2 (18-43) 0.96
Parity2,4, n (%)
1 235 (19%) 65 (15%)
2 663 (53%) 233 (55%)
3 280 (23%) 100 (24%)
≥ 4 65 (5%) 24 (6%)
Mean (range) 2.16 (1-6) matched 2.20 (1-6) matched
Breastfeeding, mean months3,4 (range) 10.4 (0-92) 8.8 (0-84) 0.0009 9.7 (0-94) 10.2 (0-86) 0.56
Oral contraceptive use4, ever, n (%) 644 (52%) 657 (53%) 0.95 348 (83.5%) 336 (80.2%) 0.22
Smoking status, ever, n (%) 549 (45%) 574 (46%) 0.74 185 (44.4%) 170 (40.9%) 0.31
Alcohol use, ever, n (%) 832 (67%) 760 (61%) 0.002 305 (73.3%) 284 (68.8%) 0.13
HRT use4, n (%) 148 (12%) 67 (5%) < 0.0001 69 (16.5%) 45 (10.7%) 0.02
BMI at age 30, mean (range) 22.5 (13-47) 22.6 (9-62) 0.24 22.8 (15-54) 23.0 (12-65) 0.48
1n/a, not applicable. 2Parity includes live births only. 3Breastfeeding is the total months of breastfeeding for each pregnancy combined. 4Parity, breastfeeding,
oral contraceptive use and HRT use were censored one year prior to the diagnosis of the matched case for both cases and controls.
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compared with never breastfeeding by age at diagnoses
≤ 39, 40 to 49 and ≥ 50 were 0.98 (95% CI 0.37 to 2.62),
1.41 (95% CI 0.59 to 3.43) and 0.91 (95% CI 0.24 to
3.43), respectively.
Discussion
The goal of the current study was to evaluate the rela-
tionship between breastfeeding and breast cancer risk
among women with a BRCA1 or BRCA2 mutation.
Because of the strong relationship between parity and
breastfeeding, we limited our analysis to parous women
and we matched cases and controls on parity. Here we
report that ever having breastfed and the total duration
of breastfeeding conferred substantial reductions in
breast cancer risk among BRCA1, but not BRCA2 muta-
tion carriers. Breastfeeding for one or more years con-
ferred a significant 32% reduction in risk in BRCA1
mutation carriers. These findings are in agreement with
our earlier publication, which was based on a subset of
these women [11]. In the present study, we expand our
study sample from 995 to 1,665 matched pairs and we
have matched on parity. The current study provides the
most up-to-date evaluation of this association and should
be helpful for genetic counsellors. The current study per-
tains to women who choose not to have a bilateral mas-
tectomy; among women who have had preventive
surgery, the risk of breast cancer is sufficiently low that
they are not impacted adversely by the inability to
breastfeed.
Other groups that have evaluated the relationship
between breastfeeding and breast cancer risk among
BRCA mutation carriers reported no relationship
between breastfeeding and risk [8-10], although these
studies were limited by small sample sizes and the mer-
ging of women who were carriers of a BRCA1 or
BRCA2 mutation. These findings extend our previous
report that breastfeeding for more than one year reduces
risk among BRCA1, but not among BRCA2 mutation
carriers [11].
In a collaborative re-analysis of data from 47 indepen-
dent epidemiologic studies conducted among women in
the general population, the authors reported a 4.3%
reduction in breast cancer risk for every 12 months of
breastfeeding (95% CI 2.9 to 5.8; P < 0.0001) [2]. The
effect of breastfeeding among BRCA1 mutation carriers
reported here is much greater than that reported in the
general population (19% vs. 4.3% reduction in risk per
year of breastfeeding). In BRCA mutation carriers specifi-
cally, it does not appear that parity per se influences the
risk of breast cancer independently of breastfeeding. The
majority of BRCA1-related tumors are basal-like breast
cancers characterized by ER, PR and HER2 negativity
Table 2 Relationship between duration of breastfeeding and risk of breast cancer among BRCA1 and BRCA2 mutation
carriers.
Breastfeeding duration N
(cases/controls)
Univariate
OR (95% CI)
P Multivariate1
OR (95% CI)
P
All subjects 1,665/1,665
Never 389/327 1.00 (reference) 1.00 (reference)
Ever 1,276/1,338 0.79 (0.67 to 0.94) 0.007 0.81 (0.68 to 0.97) 0.02
> 0 to ≤ 12 months 846/845 0.83 (0.69 to 0.99) 0.04 0.84 (0.70 to 1.02) 0.08
> 12 to ≤ 24 months 285/318 0.72 (0.58 to 0.90) 0.005 0.73 (0.58 to 0.93) 0.01
> 24 months 145/175 0.65 (0.49 to 0.86) 0.003 0.66 (0.49 to 0.89) 0.007
Per year 0.90 (0.84 to 0.97) 0.008 0.87 (0.79 to 0.95) 0.002
BRCA1 1,243/1,343
Never 267/213 1.00 (reference) 1.00 (reference)
Ever 976/1,030 0.74 (0.61 to 0.92) 0.005 0.76 (0.61 to 0.95) 0.02
> 0 to ≤ 12 months 669/658 0.79 (0.64 to 1.00) 0.03 0.81 (0.64 to 1.01) 0.06
> 12 to ≤ 24 months 212/236 0.68 (0.52 to 0.88) 0.004 0.68 (0.52 to 0.91) 0.008
> 24 months 94/136 0.50 (0.35 to 0.70) < 0.0001 0.51 (0.35 to 0.74) 0.0003
Per year 0.84 (0.77 to 0.93) 0.0003 0.81 (0.73 to 0.91) 0.002
BRCA2 422/422
Never 122/114 1.00 (reference) 1.00 (reference)
Ever 300/308 0.91 (0.67 to 1.23) 0.53 0.90 (0.64 to 1.25) 0.51
> 0 to ≤ 12 months 177/187 0.89 (0.64 to 1.23) 0.47 0.89 (0.63 to 1.25) 0.49
> 12 to ≤ 24 months 72/82 0.84 (0.54 to 1.28) 0.40 0.83 (0.53 to 1.31) 0.43
> 24 months 51/39 1.21 (0.72 to 2.03) 0.48 1.20 (0.68 to 2.11) 0.53
Per year 1.05 (0.91 to 1.21) 0.51 1.02 (0.85 to 1.21) 0.87
1Estimate adjusted for age at menarche (continuous), age at first birth (continuous), age at first birth (continuous), alcohol consumption (ever/never) and HRT use
(ever/never).
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while BRCA2-tumors resemble sporadic cases [13]. Other
groups have shown that parity is a risk factor, while
breastfeeding protects against the development of basal-
like or ER-negative/PR-negative breast cancers in the
general population [14-16]. Likewise, differences in the
pathologic features of BRCA1 and BRCA2 tumors may
also reflect etiologically distinct tumors and possibly dif-
ferences in risk factor associations.
Several mechanisms have been proposed to explain the
biologic basis for the inverse relationship between breast-
feeding and breast cancer risk (reviewed in [17]). These
include: 1) hormonal changes, particularly a reduction in
endogenous estrogen and progesterone levels and/or
increased prolactin levels; 2) excretion of estrogens and
carcinogens from the breast ducts; 3) breast tissue differ-
entiation; and 4) a delay in the establishment of regular
ovulation and, subsequently, the cumulative number of
ovulatory cycles [17]. We have recently shown that the
number of lifetime ovulatory cycles does not influence
breast cancer risk in women with BRCA1 or BRCA2
mutations (JK, JL, HTL, C K-S, SN, RD, WDF, PG, NT,
PA, LS, Beth Karlan, AE, CE, Jeffrey Weitzel, DMG, JB,
Dana Zakalik, CS, Taya Fallen, OG, TH, PS, SAN,
Oophorectomy after Menopause and the Risk of Breast
Cancer in BRCA1 and BRCA2 Mutation Carriers, sub-
mitted). Our data presented in this manuscript support
the first three hypotheses and are reinforced by the long
lasting effect of breastfeeding among BRCA1 mutation
carriers. Breastfeeding for at least one year significantly
reduced the risk of breast cancer diagnosed under the
age of 50. Although the association did not achieve statis-
tical significance (likely due to small numbers), this pro-
tective effect was also apparent for those diagnosed ≥ 50
and was indicative of a long-term reduction in risk with
breastfeeding.
Experimental evidence supports an important role of the
BRCA1 protein in mammary cell differentiation and pro-
liferation. Rajan and colleagues have shown that BRCA1
and BRCA2 mRNA expression is high in proliferating cells
in mice during periods of rapid proliferation and differen-
tiation, such as embryogenesis, puberty and pregnancy,
but is low during lactation [18-20]. In addition, the BRCA
proteins interact with STAT5a, a mammary gland tran-
scription factor that is stimulated by prolactin at the end
of pregnancy, and which is involved in the growth and
terminal differentiation of breast epithelial cells [21]. Thus,
among women with a mutation and one functional allele,
one would expect that breast cell differentiation from
breastfeeding might be compromised.
In vivo studies have shown that a conditional mutation
in Brca1 in mouse mammary epithelial cells results in
defective development of mammary tissue during preg-
nancy and lactation [22,23]. Further, Russo et al. have
reported that the developmental pattern of breast tissue
from parous women with a family history of breast can-
cer or BRCA1 mutation was comparable to that from
nulliparous women with no family history (that is, did
not differentiate with parity) [24]. Collectively, the evi-
dence supports an important role of the BRCA proteins
in breast tissue differentiation during pregnancy and/or
lactation.
Based on our findings to date, it appears that cumula-
tive sex hormone exposure, particularly estrogen, is likely
involved in the development of breast cancer in BRCA1
mutation carriers. Late age at menarche, breastfeeding
and bilateral salpingo-oophorectomy are protective; while
the role of parity is less clear. Recent studies have identi-
fied an important role for progesterone in regulating the
number of stem cells in normal human and mouse mam-
mary glands [25,26]. The terminal differentiation of
mammary stem cells during the process of breastfeeding
may be protective since this process can deplete the pool
of potentially deleterious stem cells or by reducing the
number of stem cells at risk of mutation. If confirmed,
agents that can mimic the terminal differentiation pro-
cess, or otherwise reduce the size of the stem cell popula-
tion, may be effective in reducing breast cancer risk.
Notably, it has been reported that heterozygosity of
BRCA1 may result in abnormal self-renewal of breast
cancer stem cells [27]. Specifically, failure of terminal dif-
ferentiation after pregnancy in BRCA1 mutation carriers
resulted in an increased risk of breast cancer [28].
Strengths of the current study include the large num-
ber of known BRCA mutation carriers and the ability to
conduct a matched analysis to ensure that the case and
control subjects were similar. The sample size range in
four prior studies was 94 to 1,601 BRCA carriers [8-11].
To determine the effect of breastfeeding on cancer risk
independent of the effects of parity, we limited our analy-
sis to parous women and matched for parity. We con-
trolled for other known or suspected risk factors for
breast cancer in our multivariate models, thus decreasing
the influence of confounding although our adjusted and
unadjusted results did not differ substantially.
The main limitation of our study was the use of self-
reported breastfeeding which may have led to measure-
ment error; however, an earlier validation study by Kark et
al. reported high concordance between breastfeeding
derived from clinic records compared with an interview
conducted 20 to 22 years later (Spearman P = 0.86) [29].
A role of recall bias is unlikely given that there is no rea-
son for women to suspect a role of breastfeeding in the
etiology of their disease. In addition, we were not able to
differentiate between women who exclusively breastfed
versus those who also supplemented with bottle feeding.
Despite this, with 1,665 matched pairs, this is the largest
study to date addressing the role of breastfeeding in the
etiology of BRCA-associated breast cancer development.
Kotsopoulos et al. Breast Cancer Research 2012, 14:R42
http://breast-cancer-research.com/content/14/2/R42
Page 5 of 7
Conclusions
In summary, these findings corroborate a protective role
of breastfeeding on breast cancer risk for BRCA1. The
lack of an association for BRCA2 mutation carriers sug-
gests that the biological pathway for carcinogenesis is
different for the two genes. Women with a BRCA muta-
tion should be advised of the benefit of breastfeeding in
terms of reducing breast cancer risk.
Abbreviations
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